Insiders who reported open-market trades in the last 12 months at the companies Jason V. Coloma files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Harold Bernstein - $7.44M in MAZE purchases and sales in the last 12 months
Atul Dandekar - $2.27M in MAZE purchases and sales in the last 12 months
Catherine A. Sohn - $1.15M in MAZE purchases and sales in the last 12 months
Amy Bachrodt - $757K in MAZE purchases and sales in the last 12 months
Phillips Courtney - $105K in MAZE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Jason V. Coloma is a corporate insider, tracked as Chief Executive Officer, Director of Maze Therapeutics, Inc. (MAZE). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jason V. Coloma submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has Jason V. Coloma been buying or selling stock?
Recorded transactions: 0 open-market purchases and 25 open-market sales ($6.19M) across all tracked filings.
Jason V. Coloma is Chief Executive Officer, Director of Maze Therapeutics, Inc. (MAZE). 11 SEC Form 4 filings on record going back to 2025, most recently on 2 October 2026. Most recent open-market trade: sold $862K of MAZE on 2 October 2026. Lifetime open-market sales: $6.19M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Jason V. Coloma.
InsiderAlpha's records for Jason V. Coloma go back to 2025: 11 primary Form 4 filings, an average of 5.5 per year. 23 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
